Vilgrain, Valérie <br/><br/>
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.  [electronic resource] 

 -  Trials  Dec 2014 
 - 474 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1745-6215 
<br/><br/><label>Standard No.: </label>10.1186/1745-6215-15-474  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Hepatocellular--economics<br/>Clinical Protocols<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Disease-Free Survival<br/>Drug Costs<br/>Embolization, Therapeutic--adverse effects<br/>France<br/>Humans<br/>Liver Neoplasms--economics<br/>Microspheres<br/>Niacinamide--adverse effects<br/>Phenylurea Compounds--adverse effects<br/>Prospective Studies<br/>Protein Kinase Inhibitors--adverse effects<br/>Quality of Life<br/>Research Design<br/>Sorafenib<br/>Time Factors<br/>Treatment Outcome<br/>Yttrium Radioisotopes--administration & dosage